salarius
pharmaceuticals
present
upcoming
investor
conferences
houston
globe
newswire
salarius
pharmaceuticals
nasdaq
slrx
oncology
company
targeting
cancers
caused
dysregulated
gene
expression
today
announced
participation
two
upcoming
investor
conferences
month
september
presentations
david
arthur
chief
executive
officer
salarius
pharmaceuticals
provide
overview
salarius
business
highlight
recent
achievements
well
anticipated
upcoming
clinical
program
milestones
company
lead
drug
candidate
seclidemstat
reversible
inhibitor
studied
phase
clinical
trial
ewing
sarcoma
rare
deadly
pediatric
bone
cancer
second
trial
advanced
solid
tumors
ast
studies
dose
escalation
thus
far
seclidemstat
shown
tolerable
safety
profile
increases
patient
exposure
levels
members
salarius
management
team
available
participate
virtual
meetings
investors
registered
attend
conferences
details
salarius
presentations
follows
event
wainwright
annual
global
investment
conference
date
wednesday
september
time
pm
et
live
webcast
https
webcast
slrx
event
virtual
life
science
investor
forum
date
thursday
september
time
pm
et
live
webcast
https
live
webcast
presentation
available
clicking
provided
link
visiting
upcoming
events
section
company
website
salarius
pharmaceuticals
salarius
pharmaceuticals
oncology
company
targeting
cancers
caused
dysregulated
gene
expression
developing
treatments
patients
need
epigenetics
refers
regulatory
system
affects
gene
expression
salarius
lead
candidate
seclidemstat
currently
phase
clinical
trial
relapsed
refractory
ewing
sarcoma
received
fast
track
designation
orphan
drug
designation
rare
pediatric
disease
designation
food
drug
administration
salarius
also
developing
seclidemstat
several
cancers
high
unmet
medical
need
second
phase
clinical
study
advanced
solid
tumors
including
prostate
breast
ovarian
cancers
salarius
received
financial
support
national
pediatric
cancer
foundation
advance
ewing
sarcoma
clinical
program
also
recipient
million
product
development
award
cancer
prevention
research
institute
texas
cprit
information
please
visit
statements
news
release
includes
statements
within
meaning
federal
securities
laws
statements
involve
substantial
risks
uncertainties
including
statements
based
current
expectations
assumptions
company
management
statements
statements
historical
facts
included
press
release
regarding
company
plans
objectives
expectations
assumptions
management
statements
use
certain
words
including
words
estimate
project
intend
expect
believe
anticipate
plan
could
may
similar
expressions
intended
identify
statements
company
may
actually
achieve
plans
intentions
expectations
disclosed
statements
place
undue
reliance
company
statements
various
important
factors
could
cause
actual
results
events
differ
materially
may
expressed
implied
statements
including
receipt
regulatory
approvals
market
conditions
statements
made
date
company
undertake
obligation
update
statements
whether
result
new
information
future
events
otherwise
contact
investor
relations
tiberend
strategic
advisors
maureen
mcenroe
cfa
miriam
miller
mmcenroe
mmiller
